Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.55 |
| ▸ | CES1 | P23141 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201027 | 0.92 | MEN1 (0.51) | CES2CES1LMNAALDH1A1TDP1 | |
| SCHEMBL627867 | 0.88 | CES2 (0.64) | CES2CES1LMNAALDH1A1TDP1 | |
| SCHEMBL2976217 | 0.85 | LMNA (0.57) | CES2CES1LMNAALDH1A1TDP1 | |
| SCHEMBL627839 | 0.83 | CES2 (0.53) | CES2CES1LMNATDP1L3MBTL1 | |
| SCHEMBL5873117 | 0.83 | LMNA (0.50) | CES2CES1LMNAALDH1A1TDP1 | |
| SCHEMBL682581 | 0.83 | CES2 (0.53) | CES2CES1LMNAALDH1A1TDP1 | |
| SCHEMBL7855318 | 0.83 | ALOX15 (0.48) | CES2CES1LMNAALDH1A1TDP1 | |
| SCHEMBL13178294 | 0.83 | GSK3B (0.60) | CES2CES1LMNAALDH1A1TDP1 | |
| SCHEMBL5334151 | 0.81 | KMT2A (0.53) | CES2CES1ALDH1A1MEN1KMT2A | |
| SCHEMBL5319603 | 0.81 | KMT2A (0.53) | CES2CES1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021114801-A1 | IMIDAZOPYRIDINE-BASED ARYLAMINE COMPOUND AND USE THEREOF | 广东阿格蕾雅光电材料有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021103769-A1 | COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE CONTAINING THE COMPOUND | 广东阿格蕾雅光电材料有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2020228430-A1 | IMIDAZO NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 广东阿格蕾雅光电材料有限公司 | 2020-11-19 | — | — | WO | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| EP-1748993-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-02-07 | — | — | EP | disclosed |
| US-20060141043-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides | ASTRAZENECA A B (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| WO-2005116000-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | disclosed |
| EP-1592403-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE THIAZOLE DERIVATIVE AND EXCIPIENTS LIKE MIDDLE CHAIN TRIGLYCERIDES | AstraZeneca AB (SE) | 2005-11-09 | — | — | EP | disclosed |
| EP-1581214-A1 | 4,5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | Astrazeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004069226-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE THIAZOLE DERIVATIVE AND EXCIPIENTS LIKE MIDDLE CHAIN TRIGLYCERIDES | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004058255-A1 | 4, 5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | PPARG, PPARA, PPARD | CES2 1636/4885CES1 145/4885LMNA 1550/4885 |
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | CNR1, CNR2, NPY4R | CES2 654/4885CES1 372/4885LMNA 4586/4885 |
| US-20060141043-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides | CETP, LIPC, LIPA | CES2 1060/4885CES1 48/4885LMNA 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.